title: Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with 111In-pentetreotide.
abstract: In-111 pentetreotide is a new radiolabelled [OctreoScan 111, Mallinckrodt Medical BV, Petten] somatostatin analog with high affinity to somatostatin receptors (SR). introduced for the in vivo imaging of SR positive tissues. In an attempt to evaluate its clinical usefulness for tissue characterization in malignancies without neuroendocrine expression in parallel with histological and radiological examinations, specific scintigraphy was performed on brain (6 cases), thyroid (6 cases) and breast (9 cases) tumors, and in lymphomas (9 cases) and melanomas (6 cases). A dose of 111MBq of In-111 pentetreotide was injected i.v. to each patient and scintimages at 6 and 22 hours (for comparison) p.i. were obtained. The primary lesion of the breast cancer population was imaged in all 9 cases as well as all the palpable axillary nodes in 4 cases. Three women with impalpable axillary lymph nodes scanned negative but had a positive biopsy. Both meningiomas were positive for SR scans: positive results were also obtained for the high grade astrocytoma and the craniopharyngioma: Two out of 6 patients with papillary thyroid cancer showed a marked radiotracer accumulation. Scintigraphy in all 5 lymphomas was positive for SR but did not detect the Tc-99m sulphur microcolloid [Lymphoscint, Solco, Basel, Suitzerland] imaged lymph nodes in 5 melanomectomized patients. When judging the imaging results of these non-neuroendocrine malignancies definite conclusions should not be drawn since the number of studied cases polymorph, was small for every cancer histotype; nevertheless SR scintigraphy does not seem to be reliable for tumor staging in non-neuroendocrine malignancies, but is more suitable for a tissue characterization and monitoring changes of SR expression during and after therapy.
authors.affiliation: Department of Radiology, Areteion University Hospital, Athens University Medical Faculty, Greece.
authors.forename: G S
authors.initials: GS
authors.lastname: Limouris
authors.forename: A
authors.initials: A
authors.lastname: Rassidakis
authors.forename: A
authors.initials: A
authors.lastname: Kondi-Paphiti
authors.forename: N
authors.initials: N
authors.lastname: Triantafyllou
authors.forename: A
authors.initials: A
authors.lastname: Manetou
authors.forename: V
authors.initials: V
authors.lastname: Giannakopoulos
authors.forename: N
authors.initials: N
authors.lastname: Toubanakis
authors.forename: I
authors.initials: I
authors.lastname: Psyhojios
authors.forename: A
authors.initials: A
authors.lastname: Stavraka
authors.forename: L
authors.initials: L
authors.lastname: Vlahos
mesh_terms: D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D008207:Lymphatic Metastasis; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging* / Q000473:pathology; D017481:Receptors, Somatostatin / Q000032:analysis*; D012878:Skin Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D013004:Somatostatin / Q000031:analogs & derivatives*; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D014055:Tomography, Emission-Computed
chemical_list: D007205:Indium Radioisotopes; D017481:Receptors, Somatostatin; D013004:Somatostatin; C081788:pentetreotide